この記事を読む

TKIと殺細胞性抗がん剤併用の再現性

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer. Noronha V et al. J …

この記事を読む

免疫療法単剤、腫瘍マーカー低下も早期効果指標となる

Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1/PD-L1 inhibitor treated a…

この記事を読む

維持療法に適しているのはベバシズマブ、ペメトレキセド、それとも両者?

Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: …

この記事を読む

ADAと免疫療法

Correlation between serum adenosine deaminase activity and efficacy of anti-programmed cell death-1 antibody. Saiki M et…

この記事を読む

HPDは疲弊T細胞と関連する

Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Kim CG, Ann Oncol. 2019…

この記事を読む

輸血の既往が予後を変える?

Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy. Sa…

この記事を読む

アファチニブのlast resort

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Schu…

この記事を読む

ICIにおける脳転移の予後

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. Hendriks LE…

この記事を読む

EGFR-TKIへの耐性機序としてのBRAF rearrangements

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. Vojnic M et al. J…

この記事を読む

KRAS陽性に対する免疫治療

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Jeanson A et al. J Thorac On…